Takeda Pharmaceutical Company Ltd (Takeda) has launched "Takepron IV for injection 30mg" (generic name: lansoprazole) in Japan for the treatment of peptic ulcer as an additional dosage formulation to the current oral ones.
Lansoprazole is a proton pump inhibitor discovered and developed by Takeda, and the newly launched injectable formulation was approved for bleeding associated with gastric ulcer, duodenal ulcer, acute stress ulcer and acute gastric mucosal lesion for the patients who are not able to take the drug orally. The approved dosage and administration is 30mg twice a day.
"Takepron has evidenced efficacy for suppression of gastric acid secretion from the parietal cell," said Makoto Yamaoka, senior managing director, general manager of Pharmaceutical Marketing Division of Takeda. "With the addition of the injectable formulation, we believe the product line of Takepron will be further contributing to treatment of patients with peptic ulcers since Takepron has been approved for a variety of indications while it is available in the administration/treatment options such as orally disintegrating tablets that can be taken without water, and the product in one package with other medications for eradication of Helicobactor pylori."